EUVIMEDEUVIMED entdecken
Crossref

Quantification of Remimazolam Besylate (CNS7056B) and Its Metabolite (CNS7054X) by LC–MS/MS in Human Plasma Using Midazolam-d4 Maleate as Internal Standard

Stefanie Schmidt iD, Ljubica Krajinovic, Christian Mertens, Lisa Schramm, Jürgen Schüttler, Jörg Fechner

Journal of Chromatographic Science · 2024

DOI: 10.1093/chromsci/bmac097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chromatographic Science, 2024. Verfasst von Stefanie Schmidt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Friedrich-Alexander-University of Erlangen-Nuremberg, Krankenhausstraße 12, 91054 Erlangen, Germany. Hauptthemen laut MEDLINE: Midazolam, Tandem Mass Spectrometry, Benzodiazepines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: PAION GmhH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new assay was developed to measure the concentration of remimazolam besylate (CNS7056B) and its major carboxylic acid metabolite (CNS7054X) in human plasma. For this new assay method, midazolam-d4 maleate was used as an internal standard. After setting up a previously described assay method, using CNS7056-d4 and CNS7054-d4 as internal standards, analytical results of both methods were compared. For the new analytical method, ultra-high-performance liquid chromatography (UHPLC) with tandem mass spectrometry was applied. A purification method, using solid phase extraction, was developed and validated. The chromatographic separation of the analytes was achieved with a mobile phase gradient using a Water Acquity™ UHPLC-System. The Kinetex™ biphenyl 50 × 2.1 mm UHPLC column was used with a particle diameter of 1.7 μm (Phenomenex, Germany). A measuring range of 0.6–2,000 ng/mL for CNS7056B and of 6–20,000 ng/mL for CNS7054X could be achieved with this new assay. The lower limit of quantification was 0.6 ng/mL for CNS7056B and 6 ng/mL for CNS7054X. The assay was validated according to US Food and Drug Administration guidelines. The new method showed an accuracy of 96.9–110.4% and a precision of 2.1–6.7% for both analytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MidazolamTandem Mass SpectrometryBenzodiazepinesHumansChromatography, LiquidLiquid Chromatography-Mass SpectrometryChromatography, High Pressure LiquidMaleatesReproducibility of Results

Substanzen

remimazolamMidazolamMaleatesBenzodiazepines

Autor:innen und Institutionen

  • Department of Anesthesiology, Friedrich-Alexander-University of Erlangen-Nuremberg, Krankenhausstraße 12, 91054 Erlangen, Germany.

ORCID-Profile: Stefanie Schmidt

Förderung

  • PAION GmhH

Zitieren

APA

Schmidt, S., Krajinovic, L., Mertens, C., Schramm, L., Schüttler, J., & Fechner, J. (2024). Quantification of Remimazolam Besylate (CNS7056B) and Its Metabolite (CNS7054X) by LC–MS/MS in Human Plasma Using Midazolam-d4 Maleate as Internal Standard. Journal of Chromatographic Science. https://doi.org/10.1093/chromsci/bmac097

Vancouver

Schmidt S, Krajinovic L, Mertens C, Schramm L, Schüttler J, Fechner J. Quantification of Remimazolam Besylate (CNS7056B) and Its Metabolite (CNS7054X) by LC–MS/MS in Human Plasma Using Midazolam-d4 Maleate as Internal Standard. Journal of Chromatographic Science. 2024. doi:10.1093/chromsci/bmac097

BibTeX
@article{Schmidt2024,
  author = {Schmidt, Stefanie and Krajinovic, Ljubica and Mertens, Christian and Schramm, Lisa and Schüttler, Jürgen and Fechner, Jörg},
  title = {Quantification of Remimazolam Besylate (CNS7056B) and Its Metabolite (CNS7054X) by LC–MS/MS in Human Plasma Using Midazolam-d4 Maleate as Internal Standard},
  journal = {Journal of Chromatographic Science},
  year = {2024},
  doi = {10.1093/chromsci/bmac097}
}
Kostenlos starten →